A New Class of
Synthetic Anti-Infectives
About
Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.
Proprietary new class of anti-infectives against bacteria and viruses
Designed to work against antibiotic-resistant bacteria
Multiple clinical indications and formulations including registrational Phase 3 trials in Indonesia and Australia, addressing unmet medical needs
A Universal Mechanism of Action
Recce’s New Class of Synthetic Anti-Infectives have a universal mechanism of action with the ability to overcome hyper-cellular mutation of bacteria and viruses. Recce’s anti-infectives are unique – their potency does not diminish even with repeated use, a common failure associated with existing drugs.
Recce continues to strengthen and expand its product pipeline of therapeutic options for ‘difficult to treat’ bacterial infections – including their mutated forms.
Company
Announcements
Sign up for news and updates
Receive news and updates direct to your inbox.
Kun suomalaiset etsivät nopeaa ja luotettavaa pelipaikkaa, Ala Win Casino nousee usein esiin monipuolisen pelivalikoimansa ja selkeän käyttöliittymänsä ansiosta.
Kdo hledá rychlé vklady bez zbytečného ověřování, měl by zvážit online casino bez bankovního účtu a porovnat dostupné bonusy i herní nabídku u různých operátorů.